Medical-device commercialization begins by separating a product claim from the evidence supporting that intended use. Two imaging algorithms may share similar architecture yet face different workflows, patient populations and submission pathways. A rigorous assessment distinguishes prototype performance from the data, controls and usability evidence available for an identifiable device configuration.
Medical-device commercialization begins by separating a product claim from the evidence supporting that intended use. Two imaging algorithms may share similar architecture yet face different workflows, patient populations and submission pathways. A rigorous assessment distinguishes prototype performance from the data, controls and usability evidence available for an identifiable device configuration.
This page concerns research and strategic decision support for Medical-device manufacturers, digital-health founders and investors. The starting point is a defined decision—such as technology selection, partnership diligence, investment screening or a product roadmap—not an assumption that a published demonstration applies to every commercial setting.
Evidence should be identified by date, source, applicable product configuration and test boundary. Supplier claims, patents, industry standards, peer-reviewed results and official permissions answer different questions. A reliable brief records disagreements among them and identifies the information that remains unavailable, rather than treating missing information as evidence of suitability.
Review intended-use statements alongside what the output actually changes in diagnosis, monitoring or care. Compare device classes only where product function and user population are sufficiently similar; a clinical decision-support tool cannot be evaluated solely as a consumer dashboard.
Specify data sources, exclusions and decision criteria before treating a technical claim as a commercial conclusion.
Ask whether a study reflects intended patients and operating sites, and whether training data, external validation and missing cases are disclosed. Performance reported from a single centre does not automatically transfer to another scanner, population or prevalence setting.
Specify data sources, exclusions and decision criteria before treating a technical claim as a commercial conclusion.
Trace specifications, human factors, software revisions, verification records and patent claims to specific device features. A patent does not verify effectiveness, and a clearance for one device should not be attributed to another product.
Specify data sources, exclusions and decision criteria before treating a technical claim as a commercial conclusion.
The following are illustrative research products, not claims of work previously performed for a named client. Final deliverables depend on the source material supplied, jurisdiction, technical configuration and commercial objective.
Create a versioned source register, compare suppliers or methods under explicit inclusion criteria, and identify where a critical assumption lacks independent support. The output should tell the decision maker what is known, what is inferred and what needs further testing.
For medical devices and diagnostics, this output should be tailored to the relevant product, use case and the supporting evidence identified in the preceding research dimensions.
Translate the research into alternatives: baseline, pilot and phased deployment. Identify dependencies such as data availability, specialist review, commercial rights and implementation costs. Highlight sensitivity to assumptions rather than presenting a single guaranteed outcome.
For medical devices and diagnostics, this output should be tailored to the relevant product, use case and the supporting evidence identified in the preceding research dimensions.
Prepare a practical issue register for partners and internal teams. Associate each open question with the evidence needed to resolve it, responsible decision owner and potential effect on timing, commercial terms or technical suitability.
For medical devices and diagnostics, this output should be tailored to the relevant product, use case and the supporting evidence identified in the preceding research dimensions.
A manufacturer considering an AI-assisted screening module needs to compare three suppliers. The review would first fix the clinical use case and deployment environment, then index each supplier’s performance evidence, approval status, product versions, integration interfaces and licensing terms. The decision memo should identify evidence missing for each shortlisted supplier before procurement proceeds.
Before any decision memo is finalized, test a negative scenario: what if the best-looking solution performs materially worse in another location, changes configuration, lacks the required data rights, or cannot meet the operating environment? Counter-evidence may change the ranking or justify a smaller pilot.
Choose metrics aligned to the actual buyer decision. Each measure should have a unit, method of measurement, boundary, observation period and reason it may fail to reflect real deployment:
Report missing measurements explicitly. Differences in geography, hardware, operating time, user population and source definitions can invalidate simple comparisons. If normalization cannot be justified, present findings side by side with their limitations instead of manufacturing a composite score.
Record the decision owner, proposed use, product boundary, countries implicated and available technical evidence. Agree on exclusion criteria before selecting the preferred supplier or method.
Review primary institutional materials, peer-reviewed findings, patents and supplier records. Capture source dates, tested versions, contradictory results and uncertainty in a source ledger.
Summarize defensible options with implementation dependencies, open questions, and the responsible parties for independent professional or technical verification.
For this sector, the source-review plan should explicitly revisit intended use and regulatory classification, clinical validation and reproducibility, and design controls and patent evidence. Any material change in product configuration or commercial use may require the conclusions to be re-tested.
Research is not clinical validation, device clearance or medical advice.
Outputs are research and commercial-strategy inputs. They do not independently establish safety, regulatory approval, clinical efficacy, legal compliance, financial return or permission to operate. Jurisdiction-specific regulated professional opinions, certifications, testing and authorizations must be obtained from appropriately qualified parties when applicable.
The main institutional starting point is FDA AI-enabled medical devices. This reference provides research context, not a certification or endorsement of this website. Publication dates and current applicability should be checked at the point of engagement.
Connected technology, strategy or research context already available on this website.
Connected technology, strategy or research context already available on this website.
Explore all industry research · Consulting services · Contact and project enquiries
Start with the intended buyer decision, existing product description and any source records relevant to intended use and regulatory classification. Include dated technical results and known counterexamples; missing records can be tracked during scoping.
Research is not clinical validation, device clearance or medical advice. A research brief identifies open requirements and may coordinate questions for independent qualified reviewers; it is not a substitute for their determination.
A focused comparison may combine intended-use and evidence matrix, medical-device technology landscape and an evidence gap register. It should contain a recommendation conditional on test boundaries rather than an unconditional adoption or investment instruction.
Share the target decision, sector, key jurisdictions, available evidence, constraints and required deliverables. Use the enquiry form for structured requests or email for documents that need attachments. Engagement scope and any regulated professional requirements are confirmed individually.